article thumbnail

Ding Dong is the Skinny Label (Effectively) Dead?

FDA Law Blog

Teva case, that the statutory provisions governing patent infringement, specifically induced infringement, do not address carve-outs. Teva submitted an ANDA in 2002, and after some complicated regulatory history, ultimately carved-out the congestive heart failure indication by way of a section viii statement.

IT 52